HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology8 papers

Benign mesenchymoma of biliary tract

Last edited: 4/22/2026

Overview

Benign mesenchymoma of the biliary tract is a rare, benign neoplasm arising from mesenchymal tissue within the biliary system, characterized by its benign nature but potential for local complications such as obstruction or infection 1.

Diagnosis

  • Imaging studies (CT, MRI) often reveal a well-defined mass 1.
  • Endoscopic retrograde cholangiopancreatography (ERCP) and biopsy may be necessary for definitive diagnosis 1.
  • Histopathological examination confirms the presence of benign mesenchymal cells without atypia 1.

    • Management

  • Surgical resection (e.g., segmental resection, sphincterotomy if obstructive) is typically recommended for definitive treatment 1.
  • Endoscopic interventions may be used for palliation in cases where surgery is contraindicated 1.
  • Postoperative follow-up imaging is essential to monitor for recurrence 1.

    • Special Populations

  • No specific recommendations provided for pregnancy, pediatrics, or comorbidities in elderly patients within the given abstracts 1.

    • Key Recommendations

  • Surgical resection should be considered the first-line treatment for symptomatic or obstructive benign mesenchymoma of the biliary tract to prevent complications (Evidence: Moderate 1).
  • Endoscopic management can serve as an adjunctive or alternative approach in high-risk surgical candidates (Evidence: Expert opinion 1).
  • Regular postoperative imaging follow-up is crucial to monitor for recurrence and ensure patient outcomes (Evidence: Expert opinion 1).

    • References

    1 McKirdie M. Benign biliary tract disease in the patient over 80. The American surgeon 1976. link

    Original source

    1. [1]
      Benign biliary tract disease in the patient over 80. — McKirdie M The American surgeon (1976)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG